BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 32088737)

  • 1. KRAS mutations by digital PCR in circulating tumor cells isolated from the mesenteric vein are associated with residual disease and overall survival in resected colorectal cancer patients.
    Li Y; Monzo M; Moreno I; Martinez-Rodenas F; Hernandez R; Castellano JJ; Canals J; Han B; Muñoz C; Navarro A
    Int J Colorectal Dis; 2020 May; 35(5):805-813. PubMed ID: 32088737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Droplet digital PCR of circulating tumor cells from colorectal cancer patients can predict KRAS mutations before surgery.
    Denis JA; Patroni A; Guillerm E; Pépin D; Benali-Furet N; Wechsler J; Manceau G; Bernard M; Coulet F; Larsen AK; Karoui M; Lacorte JM
    Mol Oncol; 2016 Oct; 10(8):1221-31. PubMed ID: 27311775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue.
    Mostert B; Jiang Y; Sieuwerts AM; Wang H; Bolt-de Vries J; Biermann K; Kraan J; Lalmahomed Z; van Galen A; de Weerd V; van der Spoel P; Ramírez-Moreno R; Verhoef C; Ijzermans JN; Wang Y; Gratama JW; Foekens JA; Sleijfer S; Martens JW
    Int J Cancer; 2013 Jul; 133(1):130-41. PubMed ID: 23233388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KRAS mutation analysis of single circulating tumor cells from patients with metastatic colorectal cancer.
    Kondo Y; Hayashi K; Kawakami K; Miwa Y; Hayashi H; Yamamoto M
    BMC Cancer; 2017 May; 17(1):311. PubMed ID: 28468669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of KRAS mutations in circulating tumor cells from patients with metastatic colorectal cancer.
    Buim ME; Fanelli MF; Souza VS; Romero J; Abdallah EA; Mello CA; Alves V; Ocea LM; Mingues NB; Barbosa PN; Tyng CJ; Chojniak R; Chinen LT
    Cancer Biol Ther; 2015; 16(9):1289-95. PubMed ID: 26252055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-invasive sensitive detection of KRAS and BRAF mutation in circulating tumor cells of colorectal cancer patients.
    Mohamed Suhaimi NA; Foong YM; Lee DY; Phyo WM; Cima I; Lee EX; Goh WL; Lim WY; Chia KS; Kong SL; Gong M; Lim B; Hillmer AM; Koh PK; Ying JY; Tan MH
    Mol Oncol; 2015 Apr; 9(4):850-60. PubMed ID: 25605225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer.
    Kidess-Sigal E; Liu HE; Triboulet MM; Che J; Ramani VC; Visser BC; Poultsides GA; Longacre TA; Marziali A; Vysotskaia V; Wiggin M; Heirich K; Hanft V; Keilholz U; Tinhofer I; Norton JA; Lee M; Sollier-Christen E; Jeffrey SS
    Oncotarget; 2016 Dec; 7(51):85349-85364. PubMed ID: 27863403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment.
    Morelli MP; Overman MJ; Dasari A; Kazmi SMA; Mazard T; Vilar E; Morris VK; Lee MS; Herron D; Eng C; Morris J; Kee BK; Janku F; Deaton FL; Garrett C; Maru D; Diehl F; Angenendt P; Kopetz S
    Ann Oncol; 2015 Apr; 26(4):731-736. PubMed ID: 25628445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation between
    Aktar S; Islam F; Cheng T; Gamage SMK; Choudhury IN; Islam MS; Lu CT; Hamid FB; Ishida H; Abe I; Xie N; Gopalan V; Lam AK
    Genes (Basel); 2023 Sep; 14(9):. PubMed ID: 37761948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Droplet digital PCR revealed high concordance between primary tumors and lymph node metastases in multiplex screening of KRAS mutations in colorectal cancer.
    Vanova B; Kalman M; Jasek K; Kasubova I; Burjanivova T; Farkasova A; Kruzliak P; Busselberg D; Plank L; Lasabova Z
    Clin Exp Med; 2019 May; 19(2):219-224. PubMed ID: 30661213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of circulating tumor cells and K-ras mutations in patients with locally advanced rectal cancer: a prospective study.
    Bahnassy AA; Abdel-Azim YA; Ezzat S; Abdellateif MS; Zekri AN; Mohanad M; Salama A; Khaled H
    Mol Biol Rep; 2020 Dec; 47(12):9645-9657. PubMed ID: 33174084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of
    Olmedillas-López S; Lévano-Linares DC; Alexandre CLA; Vega-Clemente L; Sánchez EL; Villagrasa A; Ruíz-Tovar J; García-Arranz M; García-Olmo D
    World J Gastroenterol; 2017 Oct; 23(39):7087-7097. PubMed ID: 29093617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating tumor cells: exploring intratumor heterogeneity of colorectal cancer.
    Raimondi C; Nicolazzo C; Gradilone A; Giannini G; De Falco E; Chimenti I; Varriale E; Hauch S; Plappert L; Cortesi E; Gazzaniga P
    Cancer Biol Ther; 2014 May; 15(5):496-503. PubMed ID: 24521660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparative analysis of real-time quantitative PCR-Sanger sequencing method and TaqMan probe method for detection of KRAS/BRAF mutation in colorectal carcinomas].
    Zhang X; Wang Y; Gao N; Wang J
    Zhonghua Bing Li Xue Za Zhi; 2014 Feb; 43(2):77-82. PubMed ID: 24742565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Correlation of KRAS gene mutations and clinicopathologic parameters in colorectal carcinoma].
    Wang Q; Zhong M; Lü YL; Yuan J; Wei LX
    Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):603-6. PubMed ID: 23157828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acquisition of Portal Venous Circulating Tumor Cells From Patients With Pancreaticobiliary Cancers by Endoscopic Ultrasound.
    Catenacci DV; Chapman CG; Xu P; Koons A; Konda VJ; Siddiqui UD; Waxman I
    Gastroenterology; 2015 Dec; 149(7):1794-1803.e4. PubMed ID: 26341722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of circulating tumor cells (CTCs) in Egyptian non-metastatic colorectal cancer patients: A comparative study for four different techniques of detection (Flowcytometry, CellSearch, Quantitative Real-time PCR and Cytomorphology).
    Bahnassy AA; Salem SE; Mohanad M; Abulezz NZ; Abdellateif MS; Hussein M; Zekri CAN; Zekri AN; Allahloubi NMA
    Exp Mol Pathol; 2019 Feb; 106():90-101. PubMed ID: 30578762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of the combination of circulating tumor cells plus KRAS in patients with metastatic colorectal cancer treated with chemotherapy plus bevacizumab.
    Sastre J; Vidaurreta M; Gómez A; Rivera F; Massutí B; López MR; Abad A; Gallen M; Benavides M; Aranda E; Rubio ED;
    Clin Colorectal Cancer; 2013 Dec; 12(4):280-6. PubMed ID: 24012456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KRAS mutations in tumor tissue and plasma by different assays predict survival of patients with metastatic colorectal cancer.
    Xu JM; Liu XJ; Ge FJ; Lin L; Wang Y; Sharma MR; Liu ZY; Tommasi S; Paradiso A
    J Exp Clin Cancer Res; 2014 Dec; 33(1):104. PubMed ID: 25491325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab.
    Tejpar S; Celik I; Schlichting M; Sartorius U; Bokemeyer C; Van Cutsem E
    J Clin Oncol; 2012 Oct; 30(29):3570-7. PubMed ID: 22734028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.